GW’s research explores the potential therapeutic applications of cannabinoids across a broad range of disease areas for both orphan and non-orphan indications with a particular focus on neurological conditions.
GW’s proven proprietary cannabinoid product platform consists of a continually evolving library of internally generated novel cannabis plant types that produce selected cannabinoids, discovery of novel cannabinoid pharmacology through our network of world leading scientists, an intellectual property portfolio, in-house formulation, processing and manufacturing capabilities, and development and regulatory expertise. GW is in a unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale for the purposes of pharmaceutical development and to meet international regulatory requirements.
If you are interested in working with GW regarding medical education grants or specific investigator-initiated pre-clinical and clinical research, please send site and investigator information to GW via email.
For medical enquiries relating to Epidiolex (cannabidiol or CBD), contact us by filling out the form.